When was Neion Bio founded?

Neion Bio was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Neion Bio located?

Neion Bio is headquartered in New York City, United States.

Is Neion Bio a funded company?

Neion Bio is a funded company, having raised a total of $23M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 27, 2026.

When was the latest funding round of Neion Bio?

Neion Bio's latest funding was a $***** Series A round on Jun 11, 2026, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.17B in funding in 2026 to date.

Where does Neion Bio rank among its competitors?

Neion Bio ranks 19th amongst 65 active competitors, of which 20 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Neion Bio, which secured $23M in Jun, 2026.

Who are the top competitors of Neion Bio?

Neion Bio's top competitors include Senti Bio, CRISPR Therapeutics and 64x Bio. Among them, Neion Bio secured the most recent funding round in June, 2026.

Neion Bio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of life-saving products derived from nature's molecular factories. The company utilizes advanced genetic engineering that harness the power of biology to develop innovative solutions. Its technology leverages the principles of evolutionary biology to create transformative products.

Key Metrics

Founded Year

2024

Location

New York City, United States

Stage

Series A

Total Funding

$23M in 2 rounds

Latest Funding Round

Series A, Jun 11, 2026, $*****

Investors

Caffeinated & 5 more

Ranked

19^th among 65 active competitors

Similar Companies

Senti Bio & 80 more

View Neion Bio's full profile

Neion Bio has raised a total funding of $23M over 2 rounds. Its first funding round was on Mar 27, 2026. Its latest funding round was a Series A round on Jun 11, 2026 for $*****. 6 investors participated in its latest round. Neion Bio has 6 institutional investors.

Here is the list of recent funding rounds of Neion Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 11, 2026	4123285	Series A	6445297	9550898	8454546	1653576
Mar 27, 2026	3934051	Seed	3182146	5285811	Caffeinated	Basis Set Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Neion Bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neion Bio include Senti Bio, CRISPR Therapeutics and 64x Bio. Here is the list of Top 10 competitors of Neion Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, Wellington & 10 others	63/100
3rd	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	Fifty Years, Lifeforce Capital & 13 others	61/100
4th	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
5th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Fidelity Investments, Longitude Capital & 12 others	60/100
6th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, TCG Crossover ... & 17 others	58/100
7th	Logomix 2019, San Carlos (United States), Series A	Provider of genome engineering platform to create artificial cells	$22.6M	Globis Capital Partners, ITOCHU Technology Ventures ... & 15 others	57/100
8th	OXGENE 2011, Oxford (United Kingdom), Acquired	Provider of a platform for mammalian cell engineering	$28.1M	Mercia, Invesco & 6 others	57/100
9th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
10th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, Source Code Capital ... & 9 others	55/100
19th	Neion Bio 2024, New York City (United States), Series A	Developer of life-saving products derived from nature's molecular factories	$23M	Digitalis Ventures, Ensemble & 4 others	44/100